Cross Border Advisory Merger Opens New Markets for Australian Medtechs
A leading Australian medtech consultancy has merged with an international equivalent, opening the way for Australian life science companies to access broader global markets.
A trusted and long-established consultancy to the burgeoning Australian medical technology and biotechnology sectors, Brandwood CKC is now part of the privately-owned, PharmaLex Group.
The Sydney-based Brandwood CKC offers a wide range of regulatory, technical, and commercial services for developers, manufacturers and suppliers of medical devices, diagnostics and pharmaceutical products.
Services include regulatory submissions and strategy, quality management, product standards, due diligence, product development, compliance support, biocompatibility, regulator advocacy and market access initiatives.
From a boutique offering only seven years ago, Brandwood CKC has grown to over 30 consultants with a presence in Los Angeles, Wellington, Taipei and Hong Kong.
The company was formed in 2019 following the merger of Brandwood Biomedical and Capital K Consulting, both leading companies in their respective fields with 20-year histories in the business.
PharmaLex has more than 1300 employees across 40 offices in 22 countries, however until now has not had a material presence in Australia.
Brandwood CKC Managing Director, Grant Bennett, suggested the merger recognised Brandwood CKC’s track record of success across all areas, and in particular the strength in the medical devices sector.
“The merger allows us to expand the range and geographical reach of services we can provide our clients, as well as supporting PharmaLex by providing global expertise in the medical device and diagnostic sectors,” he said.
“We have always provided solid experience-backed support to clients, including access into Europe and the USA. However, having the support and access of PharmaLex in these regions, takes us to the next level,” he added.
Mr Bennett believes the combined group also provides clients with a broader network of consultants to help them expand into additional global markets with earlier market entry, as well as an expert route for offshore companies looking to enter Australia.
“Australia is a leader in the medtech and diagnostic space, with considerable government support to develop it further,” he said.
“With the exception of a few large and well-known Australian companies, most are smaller organisations facing the challenge of approaching the global market. Challenges include an understanding of the commercial horizon for their technology, regulatory implications, how to connect with the right partners and who to approach for the right advice. Brandwood CKC had shown growth in excess of 20 per cent in recent years and this momentum is expected to continue.”
“We expect continued strong growth and that is absolutely our goal. This provides the opportunity to further develop our team while providing a foothold in the Asia Pacific markets”, Mr. Bennett further stated.
He further believes that Brandwood CKC’s staffing will continue to expand post-merger.
The company will continue to operate under the Brandwood CKC name, before transitioning to PharmaLex later in the year.
PharmaLex CEO Dr Thomas Dobmeyer suggested the merger would strengthen the company’s presence in Australia and New Zealand, as well as the Asia Pacific.
“Brandwood CKC has a strong client base,” he said. “Coupled with the additional services we offer; we hope this will enable us to gain greater visibility and support our international clients to get their products successfully approved and marketed in this important region.”
Mr Dobmeyer said Brandwood CKC’s ‘Compliance with Confidence’ motto melded neatly with PharmaLex’s ‘Confidence beyond Compliance’ mantra.
He added, “this shows that both companies share the same values, mindset, and culture in being trusted partners for the biomedical industry.”
About PharmaLex <Confidence beyond compliance>:
PharmaLex is a leading provider of specialized services for the pharma, biotech and medtech industries. We guide you from early strategic planning activities and non-clinical requirements through clinical development, regulatory submission processes and post-approval / maintenance post-launch activities. Our experts use technology-enabled solutions to support you through the entire product lifecycle. We deliver exceptional results — going above and beyond the standard to deliver tailor-made solutions worldwide.
The PharmaLex Group now has over 1300 employees, with 40 offices in 22 countries and more than 600 satisfied clients worldwide.
For further information, please contact:
Ms. Eva Keck; PharmaLex GmbH; Director, Business Development Operations
+49 621 18 15 38 0
Harrlachweg 6; 68163 Mannheim; Germany
About Brandwood CKC
Brandwood CKC has a global reputation for excellence in regulatory, quality systems and commercialisation consultancy earned through service to international health innovators for more than 20 years. Brandwood CKC work with companies of all sizes across the medical, pharmaceutical and healthscience sectors, bringing deep expertise and local market knowledge to serve clients in prescription, consumer and generic medicines, medical devices, IVDs/diagnostics, and combination products.
For further information, please contact:
Yvette Elvy, Marketing Manager, Brandwood CKC
+61 416 250 858
Sydney, NSW, Australia
The views and options expressed in this article are those of the author/s and do not necessarily reflect the views of Brandwood CKC Pty Ltd ACN 128 762 505.
The information presented in this article is of a general nature only and does not consider the particular circumstances of your business. Prior results and case studies do not guarantee a similar outcome in future. You should not rely on this information, and you should seek specific advice for your particular business needs.
Where indicated, certain content has been sourced from third parties; we have not independently verified it. Neither Brandwood CKC nor the author makes any warranty as to the accuracy, completeness or reliability of this article, nor do those parties accept any liability or responsibility arising in any way from omissions or errors contained in the content.